Cartesian Therapeutics' lead asset, Descartes-08, demonstrated a 7.1-point MG-ADL reduction at 12 months in Phase 2b. Find ...
Special edition of Globe Magazine honors the best employers in Massachusetts BOSTON, MA, UNITED STATES, January 14, 2026 /EINPresswire.com/ — Cartesian has been ...
Zacks Investment Research on MSN
Cartesian Therapeutics, Inc. (RNAC) reports Q1 loss, lags revenue estimates
Cartesian Therapeutics, Inc. (RNAC) came out with a quarterly loss of $1.46 per share versus the Zacks Consensus Estimate of a loss of $0.84. This compares to a loss of $0.68 per share a year ago.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results